Our study demonstrated that 17% of patients with primary or secondary endocrine-resistant breast cancer harbored germline pathogenic variants of BRCA1, BRCA2, or PTEN. TP53 gene mutations were affected by primary endocrine resistance and poor overall survival. The gene discussed is BRCA2; the disease is breast carcinoma.